Wells Fargo’s Palvella Therapeutics PVLA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$913K Sell
6,621
-6,387
-49% -$947K ﹤0.01% 3821
2026
Q2
$1.99M Buy
13,008
+7,184
+123% +$872K ﹤0.01% 3617
2026
Q1
$726K Sell
5,824
-5,104
-47% -$532K ﹤0.01% 3939
2025
Q4
$1.14M Buy
10,928
+3,582
+49% +$306K ﹤0.01% 3864
2025
Q3
$461K Buy
7,346
+3,681
+100% +$164K ﹤0.01% 4366
2025
Q2
$82.6K Buy
3,665
+3,615
+7,230% +$84.9K ﹤0.01% 5305
2025
Q1
$1.4K Hold
50
– – ﹤0.01% 6199
2024
Q4
$600 Sell
50
-10
-17% -$157 ﹤0.01% 6301
2024
Q3
$995 Hold
60
– – ﹤0.01% 6125
2024
Q2
$589 Sell
60
-10
-14% -$113 ﹤0.01% 6134
2024
Q1
$1.02K Buy
70
+10
+17% +$139 ﹤0.01% 6147
2023
Q4
$867 Sell
60
-12
-17% -$220 ﹤0.01% 6262
2023
Q3
$1.7K Buy
72
+3
+4% +$64 ﹤0.01% 6115
2023
Q2
$920 Hold
69
– – ﹤0.01% 6336
2023
Q1
$5.35K Buy
69
+1
+1% +$116 ﹤0.01% 6035
2022
Q4
$5.7K Hold
68
– – ﹤0.01% 5732
2022
Q3
$7K Hold
68
– – ﹤0.01% 5828
2022
Q2
$10K Sell
68
-6
-8% -$1.1K ﹤0.01% 5765
2022
Q1
$18K Buy
74
+7
+10% +$1.84K ﹤0.01% 6057
2021
Q4
$20K Sell
67
-9
-12% -$2.88K ﹤0.01% 6335
2021
Q3
$32K Hold
76
– – ﹤0.01% 5798
2021
Q2
$23K Sell
76
-5,601
-99% -$1.23M ﹤0.01% 5847
2021
Q1
$1.17M Buy
5,677
+3,359
+145% +$734K ﹤0.01% 4142
2020
Q4
$464K Sell
2,318
-128
-5% -$26.6K ﹤0.01% 4572
2020
Q3
$405K Buy
2,446
+606
+33% +$138K ﹤0.01% 4503
2020
Q2
$457K Buy
1,840
+244
+15% +$57.1K ﹤0.01% 4395
2020
Q1
$291K Buy
1,596
+441
+38% +$111K ﹤0.01% 4436
2019
Q4
$334K Buy
1,155
+1
+0.1% +$277 ﹤0.01% 4666
2019
Q3
$315K Buy
1,154
+42
+4% +$16.3K ﹤0.01% 4693
2019
Q2
$419K Sell
1,112
-69
-6% -$20.6K ﹤0.01% 4505
2019
Q1
$317K Sell
1,181
-9
-0.8% -$2.14K ﹤0.01% 4591
2018
Q4
$254K Buy
1,190
+80
+7% +$24.8K ﹤0.01% 4778
2018
Q3
$497K Sell
1,110
-83
-7% -$36.1K ﹤0.01% 4443
2018
Q2
$484K Buy
1,193
+243
+26% +$116K ﹤0.01% 4476
2018
Q1
$518K Sell
950
-83
-8% -$51.4K ﹤0.01% 4358
2017
Q4
$623K Buy
1,033
+806
+355% +$375K ﹤0.01% 4236
2017
Q3
$105K Buy
+227
New +$96.9K ﹤0.01% 5214

Other funds holding PVLA

Wells Fargo's PVLA Position: Q3 2026 in Review

Wells Fargo reduced its Palvella Therapeutics (PVLA) stake by 49% in Q3 2026, selling an estimated $947K and leaving 6,621 shares worth $913K. The position accounts for ﹤0.01% of the portfolio, ranked #3821.

Wells Fargo first reported a position in PVLA in Q3 2017 and has held it in 37 quarters since. The position peaked at $1.99M in Q2 2026. 199 funds tracked by Wall St. Rank hold PVLA as of Q3 2026.

  • Wells Fargo held 6,621 shares of Palvella Therapeutics worth $913K as of Q3 2026.
  • Wells Fargo sold 6,387 Palvella Therapeutics shares in Q3 2026, an estimated $947K.
  • Palvella Therapeutics made up ﹤0.01% of Wells Fargo's portfolio in Q3 2026, its #3821 holding.
  • Wells Fargo first reported a position in Palvella Therapeutics in Q3 2017 and has held it in 37 quarters since.
  • Wells Fargo's Palvella Therapeutics position peaked at $1.99M in Q2 2026.
  • 199 funds tracked by Wall St. Rank held Palvella Therapeutics as of Q3 2026.

Based on Wells Fargo's 13F filing for Q3 2026, filed 16 Nov 2026.